REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) CEO Curran Simpson sold 20,811 shares of the company's stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $12.62, for a total transaction of $262,634.82. Following the completion of the sale, the chief executive officer directly owned 216,162 shares in the company, valued at approximately $2,727,964.44. The trade was a 8.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Curran Simpson also recently made the following trade(s):
- On Monday, September 29th, Curran Simpson sold 7,624 shares of REGENXBIO stock. The shares were sold at an average price of $10.03, for a total transaction of $76,468.72.
- On Wednesday, September 10th, Curran Simpson sold 7,734 shares of REGENXBIO stock. The shares were sold at an average price of $10.02, for a total transaction of $77,494.68.
REGENXBIO Stock Down 10.3%
NASDAQ:RGNX traded down $1.25 on Friday, reaching $10.92. The stock had a trading volume of 968,561 shares, compared to its average volume of 897,677. The company has a market capitalization of $551.61 million, a P/E ratio of -3.17 and a beta of 1.17. REGENXBIO Inc. has a 1-year low of $5.03 and a 1-year high of $12.84. The stock has a fifty day moving average price of $9.21 and a 200-day moving average price of $8.65.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). The firm had revenue of $21.36 million during the quarter, compared to analyst estimates of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%. Sell-side analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.
Institutional Investors Weigh In On REGENXBIO
Several large investors have recently bought and sold shares of RGNX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in REGENXBIO by 9.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 72,183 shares of the biotechnology company's stock valued at $558,000 after purchasing an additional 6,105 shares in the last quarter. GAMMA Investing LLC increased its stake in REGENXBIO by 372.1% in the first quarter. GAMMA Investing LLC now owns 16,188 shares of the biotechnology company's stock valued at $116,000 after purchasing an additional 12,759 shares in the last quarter. Pallas Capital Advisors LLC bought a new stake in REGENXBIO in the first quarter valued at approximately $74,000. Wealth Enhancement Advisory Services LLC bought a new stake in REGENXBIO in the first quarter valued at approximately $123,000. Finally, Janney Montgomery Scott LLC bought a new stake in REGENXBIO in the first quarter valued at approximately $484,000. Institutional investors own 88.08% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the stock. Chardan Capital restated a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Monday, September 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of REGENXBIO in a research report on Wednesday. Royal Bank Of Canada reduced their target price on shares of REGENXBIO from $21.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Barclays reduced their target price on shares of REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research report on Friday, August 8th. Finally, Wall Street Zen lowered shares of REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $28.38.
View Our Latest Analysis on REGENXBIO
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.